Your browser is no longer supported. Please, upgrade your browser.
KLDO Kaleido Biosciences, Inc. daily Stock Chart
Kaleido Biosciences, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own0.10% Shs Outstand31.88M Perf Week-29.45%
Market Cap261.49M Forward P/E- EPS next Y-2.02 Insider Trans- Shs Float10.55M Perf Month28.23%
Income-79.90M PEG- EPS next Q-0.63 Inst Own81.10% Short Float26.10% Perf Quarter19.77%
Sales0.30M P/S871.65 EPS this Y-59.90% Inst Trans0.00% Short Ratio10.02 Perf Half Y9.56%
Book/sh1.61 P/B4.63 EPS next Y-8.10% ROA-97.70% Target Price13.25 Perf Year41.37%
Cash/sh2.02 P/C3.68 EPS next 5Y- ROE-160.00% 52W Range2.82 - 11.89 Perf YTD48.41%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.08% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low152.66% ATR0.99
Employees91 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)37.37 Volatility10.42% 13.30%
OptionableNo Debt/Eq0.40 EPS Q/Q28.50% Profit Margin- Rel Volume0.42 Prev Close7.45
ShortableYes LT Debt/Eq0.40 Earnings- Payout- Avg Volume274.97K Price7.13
Recom2.00 SMA20-24.82% SMA50-9.85% SMA2002.49% Volume58,355 Change-4.36%
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
Apr-23-19Initiated Chardan Capital Markets Buy $17.50
Mar-25-19Initiated Morgan Stanley Overweight $17
Mar-25-19Initiated JP Morgan Neutral $15
Mar-25-19Initiated Goldman Buy $20
Oct-07-20 07:30AM  
Oct-06-20 07:30AM  
Oct-02-20 12:09PM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-09-20 07:00AM  
Aug-27-20 07:00AM  
Aug-06-20 11:26AM  
Aug-05-20 08:00AM  
Aug-04-20 07:35AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jun-16-20 04:45PM  
Jun-08-20 08:30AM  
Jun-07-20 08:54AM  
Jun-04-20 08:30AM  
Jun-01-20 09:30PM  
May-28-20 08:00AM  
May-27-20 03:14PM  
May-14-20 06:32AM  
May-12-20 08:30AM  
Apr-03-20 08:30AM  
Mar-31-20 11:30AM  
Mar-02-20 07:35AM  
Jan-09-20 08:00AM  
Jan-06-20 08:30AM  
Dec-22-19 01:52PM  
Dec-19-19 08:00AM  
Dec-12-19 08:00AM  
Nov-06-19 08:00AM  
Nov-05-19 01:36PM  
Oct-30-19 04:05PM  
Oct-25-19 04:44PM  
Oct-22-19 08:00AM  
Oct-03-19 08:00AM  
Sep-30-19 08:00AM  
Sep-27-19 07:56AM  
Sep-26-19 04:10PM  
Sep-09-19 07:30AM  
Sep-03-19 08:00AM  
Aug-29-19 08:00AM  
Aug-08-19 06:38AM  
Aug-01-19 07:30AM  
Jul-31-19 08:00AM  
Jul-22-19 08:00AM  
Jul-18-19 03:42PM  
Jul-15-19 08:00AM  
Jun-26-19 08:00AM  
Jun-03-19 08:00AM  
May-08-19 02:23PM  
May-02-19 07:30AM  
Apr-23-19 06:00AM  
Apr-12-19 07:30AM  
Apr-08-19 08:00AM  
Mar-27-19 08:15AM  
Mar-21-19 08:00AM  
Mar-08-19 08:30AM  
Mar-04-19 04:15PM  
Feb-28-19 11:30AM  
Feb-27-19 07:27PM  
Feb-24-19 02:34PM  
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund IV Gene10% OwnerJun 04Buy7.502,000,00015,000,0002,910,972Jun 08 04:46 PM
MELAS KYRIAZI THEODirectorJun 04Buy7.5033,333249,99833,333Jun 05 04:06 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.